Dr. Brawer left clinical practice to join GTx, Inc. and help to develop new therapies for the management of prostate cancer and related conditions. In this video he speaks about a new Phase III trial -- the TREAT 2 trial -- designed to investigate the potential of toremifene in the prevention of fractures among patients with advanced prostate cancer.
